^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Elongation factor 2 inhibitor

    Related drugs:
    Apply
    Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML (GO-TAG) (NCT05716009)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    11/20/2023
    Primary completion :
    12/25/2027
    Completion :
    12/25/2028
    CD33 • IL3RA
    |
    CD123 expression
    |
    Mylotarg (gemtuzumab ozogamicin) • Elzonris (tagraxofusp-erzs)
    Study of Tagraxofusp for Post-Transplant Maintenance for Patients with CD 123+ AML, MF and CMML (HSCT 002) (NCT05233618)
    Phase 1
    Karen Ballen, MD
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    07/13/2022
    Primary completion :
    07/01/2026
    Completion :
    10/01/2026
    IL3RA
    |
    Elzonris (tagraxofusp-erzs) • SL-701
    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (NCT03113643)
    Phase 1
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/26/2017
    Primary completion :
    05/31/2025
    Completion :
    05/31/2026
    IL3RA
    |
    CD123 expression • IL3RA expression
    |
    Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)
    Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (TAGALONG) (NCT05442216)
    Phase 2
    Joshua Zeidner
    Recruiting
    Last update posted :
    05/02/2024
    Initiation :
    05/01/2024
    Primary completion :
    08/01/2027
    Completion :
    12/01/2027
    IL3RA
    |
    CD123 positive
    |
    Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)
    Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia (NCT05720988)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Withdrawn
    Last update posted :
    03/08/2024
    Initiation :
    08/03/2024
    Primary completion :
    08/03/2025
    Completion :
    08/03/2026
    CD123 • IL3RA
    |
    CD123 positive • CD123 expression • IL3RA expression
    |
    azacitidine • Elzonris (tagraxofusp-erzs)
    Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies (NCT05476770)
    Phase 1
    Therapeutic Advances in Childhood Leukemia Cons...
    Recruiting
    Last update posted :
    02/22/2024
    Initiation :
    11/11/2022
    Primary completion :
    11/11/2025
    Completion :
    11/11/2027
    IL3RA
    |
    CD123 expression
    |
    cytarabine • azacitidine • vincristine • fludarabine IV • Elzonris (tagraxofusp-erzs)
    Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT05032183)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    10/16/2023
    Initiation :
    02/17/2022
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    IL3RA
    |
    CD123 positive
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients (NCT05734560)
    Phase 1/2
    Darell Bigner
    Recruiting
    Last update posted :
    09/21/2023
    Initiation :
    09/06/2023
    Primary completion :
    02/01/2026
    Completion :
    02/01/2028
    MGMT
    |
    RAS wild-type • IDH wild-type
    |
    D2C7
    Tagraxofusp (SL-401) in Patients With CMML or MF (Study 0314) (NCT02268253)
    Phase 2
    Stemline Therapeutics, Inc.
    Completed
    Last update posted :
    03/21/2023
    Initiation :
    12/01/2014
    Primary completion :
    03/07/2023
    Completion :
    03/07/2023
    PDGFRA • JAK2 • PDGFRB • PCM1
    |
    FGFR1 rearrangement
    |
    Elzonris (tagraxofusp-erzs)
    A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma (NCT02990416)
    Phase 1/2
    Angimmune LLC
    Unknown status
    Last update posted :
    12/13/2016
    Initiation :
    01/01/2017
    Primary completion :
    02/01/2018
    Completion :
    06/01/2018
    BRAF
    |
    Keytruda (pembrolizumab) • Resimmune (VG712)